Free Trial

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 19 +0.13 (+0.66%)
As of 11:31 AM Eastern

SBTX vs. BVXP, CIR, 4BB, HVO, AVCT, TILS, VSN, SCLP, MPH, and ORPH

Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Bioventix (BVXP), Circassia Group (CIR), 4basebio (4BB), hVIVO (HVO), Avacta Group (AVCT), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

SkinBioTherapeutics vs.

SkinBioTherapeutics (LON:SBTX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.

Bioventix has a net margin of 59.51% compared to SkinBioTherapeutics' net margin of -237.95%. Bioventix's return on equity of 69.09% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-237.95% -115.86% -61.18%
Bioventix 59.51%69.09%54.07%

Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£1.56M27.81-£3.71M-£1.63-11.69
Bioventix£13.65M10.93£8.12M£154.6218.43

SkinBioTherapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Bioventix has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Bioventix received 45 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 52.87% of users gave Bioventix an outperform vote.

CompanyUnderperformOutperform
SkinBioTherapeuticsOutperform Votes
47
60.26%
Underperform Votes
31
39.74%
BioventixOutperform Votes
92
52.87%
Underperform Votes
82
47.13%

16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 62.3% of Bioventix shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 8.0% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, SkinBioTherapeutics and SkinBioTherapeutics both had 1 articles in the media. Bioventix's average media sentiment score of 0.55 beat SkinBioTherapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SkinBioTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bioventix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bioventix beats SkinBioTherapeutics on 10 of the 14 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

MetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£43.40M£128.48M£5.31B£2.62B
Dividend YieldN/A3.74%5.20%5.05%
P/E Ratio-11.693.4126.69134.81
Price / Sales27.814,169.40393.58221,342.27
Price / Cash9.0013.1938.2528.03
Price / Book11.3233.216.743.84
Net Income-£3.71M-£91.56M£3.23B£5.88B
7 Day Performance-0.26%2.85%0.01%3.52%
1 Month Performance-24.00%7.44%8.69%25.34%
1 Year Performance90.00%101.47%18.36%130.33%

SkinBioTherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 19
+0.7%
N/A+84.5%£43.40M£1.56M-11.6911News Coverage
BVXP
Bioventix
N/AGBX 2,870
+2.5%
N/A-33.7%£150.28M£13.65M18.5612News Coverage
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
4BB
4basebio
N/AGBX 1,100
-2.2%
GBX 1,600
+45.5%
-20.7%£140.91M£311,000.00-1,410.26101News Coverage
HVO
hVIVO
N/AGBX 18.18
+0.3%
N/A-35.2%£128.60M£68.74M7.50N/ANews Coverage
AVCT
Avacta Group
N/AGBX 32.98
-3.0%
N/A-30.9%£125.30M£26.29M-4.24120News Coverage
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M£-3,595,000.00-3.5911
VSN
Verseon
N/AN/AN/AN/A£112.24MN/A-5.17N/AGap Up
SCLP
Scancell
N/AGBX 9.20
-0.5%
N/A-2.0%£95.29MN/A-14.1151News Coverage
Insider Trade
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/A-0.2150Gap Down
ORPH
Open Orphan
N/AN/AN/AN/A£67.09M£34.71M-25.30179

Related Companies and Tools


This page (LON:SBTX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners